Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chau-Dung Chang

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Chromatography. A|May 20, 2008
Rapid baseline separation of enantiomers and a mesoform of all-trans-astaxanthin, 13-cis-astaxanthin, adonirubin, and adonixanthin in standards and commercial supplementsChunlei Wang, Daniel W Armstrong, Chau-Dung Chang
Bioorganic & Medicinal Chemistry Letters|October 7, 2008
'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
European Journal of Pharmacology|February 6, 2010
KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinaseAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2008
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric siteAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Chromatography. A|May 20, 2008
Rapid baseline separation of enantiomers and a mesoform of all-trans-astaxanthin, 13-cis-astaxanthin, adonirubin, and adonixanthin in standards and commercial supplementsChunlei Wang, Daniel W Armstrong, Chau-Dung Chang
Bioorganic & Medicinal Chemistry Letters|October 7, 2008
'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
European Journal of Pharmacology|February 6, 2010
KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinaseAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2008
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric siteAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Pageof 1